| Literature DB >> 17578586 |
Jingzheng Song1, Quanbin Han, Chunfeng Qiao, Yuekeung Yip, Hongxi Xu.
Abstract
BACKGROUND: Concentrated Gegen Tang (GT) granule is a widely available traditional Chinese medicinal product for the treatment of cold and flu. There was no reliable analytical method available for the quality assessment of GT granules.Entities:
Year: 2007 PMID: 17578586 PMCID: PMC1914348 DOI: 10.1186/1749-8546-2-7
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Figure 1Chemical structures of seven chemical markers in Gegen Tang granule.
Herbal composition and daily dosage of Gegen Tang granule from four manufacturers
| - | 22.7% | 32.0% | 21.4% | |
| - | 16.6% | 16.0% | 16.1% | |
| - | 10.7% | 8.0% | 10.7% | |
| - | 11.0% | 12.0% | 10.7% | |
| - | 11.0% | 12.0% | 10.7% | |
| - | 16.6% | 4.0% | 16.1% | |
| - | 11.0% | 16.0% | 14.3% | |
| Daily dosage | 2 × 4 g | 2 × 5 g | 3 × 3 g | 2 × 5 g |
The percentage of each herbal ingredient was collected from the insert (B and C), or calculated after normalized total to 100% (D).
*The composition of A is unknown.
Regression equation, correlation coefficients, linearity ranges and limit of detection and quantitation for the markers of Gegen Tang granule
| Puerarin | 1.70 – 69.70 | 0.9997 | 6.21 | 20.70 | 0.83 | 0.78 | |
| Paeoniflorin | 1.07 – 64.36 | 0.9996 | 19.64 | 65.46 | 0.99 | 0.45 | |
| Cinnamic acid | 0.15 – 5.81 | 0.9998 | 3.72 | 12.40 | 0.61 | 0.60 | |
| Daidzain | 0.06 – 4.96 | 0.9997 | 5.58 | 18.60 | 0.33 | 1.83 | |
| Glycyrrhizin | 1.07 – 85.26 | 0.9998 | 45.47 | 151.56 | 0.10 | 1.70 | |
| Ephedrine | 1.08 – 86.13 | 0.9998 | 3.82 | 12.73 | 0.52 | 1.55 | |
| Pseudoephedrine | 2.98 – 119.13 | 0.9996 | 2.71 | 9.03 | 0.37 | 0.41 |
All regression results are statistically significant (P < 0.05)
Recovery of seven markers in Gegen Tang sample*
| Puerarin | 3920 | 0.61 | 3.50 | 3.54 | 101.20 ± 0.74 |
| 8.75 | 8.68 | 99.26 ± 0.43 | |||
| 13.85 | 13.75 | 99.41 ± 0.51 | |||
| Paeoniflorin | 3219 | 0.54 | 3.63 | 3.60 | 99.28 ± 1.61 |
| 9.07 | 8.99 | 99.14 ± 1.07 | |||
| 13.27 | 13.16 | 99.33 ± 0.51 | |||
| Cinnamic acid | 317 | 0.73 | 0.27 | 0.27 | 99.78 ± 1.01 |
| 0.68 | 0.68 | 100.23 ± 1.67 | |||
| 0.87 | 0.87 | 100.01 ± 1.06 | |||
| Daidzain | 283 | 1.14 | 0.19 | 0.19 | 100.35 ± 1.10 |
| 0.48 | 0.48 | 98.94 ± 1.50 | |||
| 0.78 | 0.77 | 98.76 ± 0.76 | |||
| Glycyrrhizin | 4138 | 0.55 | 3.56 | 3.59 | 100.92 ± 1.16 |
| 8.89 | 8.93 | 100.54 ± 0.40 | |||
| 16.96 | 17.09 | 100.73 ± 0.30 | |||
| Ephedrine | 4283 | 0.67 | 3.70 | 3.74 | 101.03 ± 0.83 |
| 9.26 | 9.30 | 100.38 ± 1.34 | |||
| 14.41 | 14.29 | 99.22 ± 1.35 | |||
| Pseudoephedrine | 1007 | 1.21 | 0.50 | 0.96 | 101.70 ± 1.17 |
| 2.37 | 2.39 | 101.02 ± 2.01 | |||
| 4.19 | 4.23 | 100.71 ± 0.72 |
*Sample Batch No. 4 from manufacturer D is used in this experiment.
Figure 2HPLC chromatograms of seven marker compounds detected in different samples under the developed mobile phase system at different detection wavelengths. Letters A, B, C and D denote the four manufacturers. Peaks: (1) Puerarin; (2) Paeoniflorin; (3) Cinnamic acid; (4) Daidzein; (5) Glycyrrhizin; (6) Ephedrine; (7) Pseudoephedrine. A2, B2, C2 and D2 are chromatograms monitored at 230 nm for the quantitative determination of paeoniflorin (peak 2) and also used for the comparison of different samples. A1, B1, C1 and D1 are chromatograms monitored at 207 nm for the determination of ephedrine (peak 6) and pseudoephedrine (peak 7). D3 is a chromatogram monitored at 250 nm for puerarin (peak 1), daidzein (peak 4) and glycyrrhizin (peak 5); and D4 is a chromatogram monitored at 275 nm for cinnamic acid (peak 3).
Contents (μg/g, mean ± SD, n = 3) of markers in Gegen Tang granule from four manufacturers
| Batch No.1 | 374.3 ± 3.1 | 270.5 ± 0.6 | 70.4 ± 0.4 | 52.1 ± 0.4 | 411.4 ± 2.8 | 731.4 ± 2.3 | 242.8 ± 2.3 | |
| Batch No.2 | 440.8 ± 1.5 | 342.1 ± 2.7 | 89.7 ± 0.5 | 59.8 ± 0.5 | 542.6 ± 2.6 | 938.5 ± 8.8 | 322.4 ± 3.1 | |
| Batch No.3 | 738.7 ± 4.1 | 353.8 ± 3.1 | 100.2 ± 0.7 | 131.4 ± 0.9 | 1558.3 ± 12.6 | 1162.0 ± 8.1 | 318.6 ± 2.0 | |
| Mean (± SD) | 517.9 ± 194.1 | 322.1 ± 45.1 | 86.8 ± 15.1 | 81.1 ± 43.7 | 837.4 ± 627.7 | 944.0 ± 215.4 | 294.6 ± 44.9 | |
| Batch No.1 | 733.4 ± 5.8 | 423.1 ± 2.0 | 72.1 ± 3.8 | 63.2 ± 1.0 | 1584.3 ± 12.2 | 2121.0 ± 7.4 | 482.6 ± 4.2 | |
| Batch No.2 | 2273.4 ± 21.4 | 1339.6 ± 4.2 | 183.4 ± 1.7 | 302.6 ± 0.7 | 3314.6 ± 14.6 | 2863.4 ± 21.8 | 891.4 ± 3.7 | |
| Batch No.3 | 1708.6 ± 11.6 | 1030.7 ± 6.5 | 149.7 ± 0.9 | 228.7 ± 0.8 | 3276.5 ± 23.9 | 1822.6 ± 0.7 | 609.7 ± 3.1 | |
| Mean (± SD) | 1571.8 ± 779.1 | 931.1 ± 466.3 | 135.1 ± 57.1 | 198.2 ± 122.6 | 2725.1 ± 988.2 | 2269.0 ± 536.0 | 661.2 ± 209.2 | |
| Batch No.1 | 1202.8 ± 14.0 | 4587.7 ± 16.1 | 224.1 ± 0.57 | 138.3 ± 0.8 | 5917.4 ± 39.1 | 2886.8 ± 0.7 | 743.7 ± 0.8 | |
| Batch No.2 | 1479.4 ± 11.5 | 1672.4 ± 10.4 | 149.6 ± 0.7 | 162.6 ± 0.1 | 1814.2 ± 5.4 | 2293.7 ± 0.2 | 639.6 ± 4.5 | |
| Mean (± SD) | 1341.1 ± 19.6 | 3130.1 ± 2061.4 | 186.9 ± 52.7 | 151.5 ± 18.6 | 3865.8 ± 2901.4 | 2590.3 ± 419.4 | 691.7 ± 10.7 | |
| Batch No.1 | 5913.6 ± 48.5 | 4899.4 ± 25.5 | 323.6 ± 1.9 | 324.1 ± 0.6 | 5087.1 ± 45.3 | 3740.4 ± 1.0 | 902.4 ± 8.1 | |
| Batch No.2 | 3417.7 ± 18.5 | 4341.6 ± 24.7 | 238.9 ± 0.6 | 179.6 ± 0.3 | 4958.3 ± 15.4 | 3172.6 ± 0.4 | 1002.4 ± 6.1 | |
| Batch No.3 | 3711.5 ± 18.6 | 4124.8 ± 32.5 | 271.4 ± 2.6 | 242.4 ± 0.9 | 4079.6 ± 11.8 | 4577.8 ± 0.8 | 1203.8 ± 6.3 | |
| Batch No.4 | 3889.3 ± 19.4 | 3128.7 ± 21.0 | 287.6 ± 2.0 | 263.7 ± 0.8 | 4189.3 ± 20.5 | 4329.6 ± 0.4 | 969.7 ± 5.2 | |
| Batch No.5 | 4193.2 ± 17.2 | 3623.3 ± 26.1 | 304.4 ± 2.7 | 269.9 ± 0.7 | 3958.7 ± 17.0 | 3820.3 ± 0.4 | 1134.3 ± 8.5 | |
| Batch No.6 | 4362.7 ± 18.6 | 3411.7 ± 14.0 | 313.2 ± 2.3 | 324.1 ± 0.5 | 4672.7 ± 20.1 | 2617.8 ± 0.8 | 933.1 ± 4.9 | |
| Batch No.7 | 4438.6 ± 31.1 | 3462.6 ± 7.6 | 327.8 ± 2.3 | 317.8 ± 0.6 | 4729.7 ± 8.5 | 2624.0 ± 0.8 | 959.7 ± 8.0 | |
| Mean (± SD) | 4275.2 ± 809.1 | 3856.0 ± 623.4 | 295.3 ± 31.8 | 274.5 ± 53.2 | 4525.0 ± 447.1 | 35554.6 ± 779.1 | 1015.1 ± 111.5 | |
Values are means ± SD of triplicate tests. Single factor ANOVA was performed on each component. Contents of each compound showed significant differences among the four manufacturers (P < 0.05). * Significant differences were observed in different sample batches (P < 0.05). ** No significant difference was observed in the contents of each component in seven batches of GT from manufacturer D (P > 0.05).
Figure 3Comparison of daily intake amounts of the seven compounds in . Letters A, B, C and D denote the four manufacturers. Values are means ± SD of batches from each manufacturer. Single factor ANOVA was performed on each compound. Contents of each compound showed significant differences among the four manufacturers (P < 0.05).